CM
VRTX icon

Crestline Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Crestline Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-7,100
Closed -$776K – 170
2017
Q1 		$776K Buy
+7,100
New +$625K 0.14% 67

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Crestline Management's VRTX Position: Q2 2017 in Review

Crestline Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2017, closing a stake of 7,100 shares — an estimated $776K sold.

Crestline Management first reported a position in VRTX in Q1 2017 and held it in 1 quarter. The position peaked at $776K in Q1 2017. 582 funds tracked by Wall St. Rank hold VRTX as of Q2 2017.

  • Crestline Management reported no remaining Vertex Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Crestline Management sold 7,100 Vertex Pharmaceuticals shares in Q2 2017, an estimated $776K.
  • Crestline Management first reported a position in Vertex Pharmaceuticals in Q1 2017 and held it in 1 quarter.
  • Crestline Management's Vertex Pharmaceuticals position peaked at $776K in Q1 2017.
  • 582 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2017.

Based on Crestline Management's 13F filing for Q2 2017, filed 14 Aug 2017.